Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000938
Chunk: 1

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 1
---
 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of January 2025

Commission File Number 001-37652

Biodexa Pharmaceuticals PLC

(Translation of registrant’s name into English)

1 Caspian Point,

Caspian Way

Cardiff, CF10 4DQ, United Kingdom

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:

Form 20-F x
Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

The information included in this Report on Form 6-K, including Exhibit 10.1 and Exhibit 10.2, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File Number 333-209365) and Form F-3 (File Number 333-267932) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

| Item 1.01. | Entry into Material Definitive Agreement. |

Securities Purchase Agreement

On
January 17, 2025, Biodexa Pharmaceuticals Plc (the “Company”) entered into a securities purchase agreement (the “Purchase
Agreement”) with C/M Capital Master Fund, LP (the “Purchaser”), pursuant to which the Company, subject to the restrictions
and satisfaction of the conditions in the Purchase Agreement, has the right, but not the obligation, to sell to the Purchaser, and the
Purchaser is obligated to purchase, up to $35 million of newly issued shares (the “Purchase Shares”) of the Company’s
American Depositary Shares (the “Depositary Shares”), each representing 10,000 of the Company’s ordinary shares, nominal
value £0.00005 each (the “Ordinary Shares”).

As consideration
for the Purchaser’s execution and delivery of the Purchase Agreement